*Please scroll down for English news
中国上海，
2022年11月23日
近期，在致力于推动女性发展和成长的公益组织sHero举办的颁奖典礼上，全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）凭借在加速倡导职场多元、平等和包容（DE&I）文化的杰出表现，荣获“2022年度最受女性欢迎雇主”银奖。
本次药明生物也入选了sHero与国际专业招聘咨询服务机构米高蒲志集团（Michael Page）联合编撰的《2022年引领多元公平包容中国最佳实践指南》（以下简称《指南》），进一步分享了公司在多元化和包容性领域的项目与举措。该《指南》汇聚了福特、索尼等30家不同行业的全球知名企业在DE&I方面的实践案例，旨在影响更多企业推广职场多元公平包容文化。
药明生物首席执行官陈智胜博士表示：“在药明生物，多元、平等和包容是我们可持续发展的重要动力，也是环境、社会及公司治理（ESG）的工作核心。此次获得‘2022年度最受女性欢迎雇主’银奖并入选《指南》，也彰显了公司ESG战略卓有成效。长期以来，我们将DE&I融入药明生物的PROUD文化，希望通过成就全球员工多元化职业成长与发展，打造赋能合作伙伴、造福广大病患的强劲引擎，共创可持续的健康未来。”
药明生物将ESG理念根植于公司战略和运营的各个环节，致力于打造安全、温暖、幸福的职场氛围和公平、公正的工作环境。全球员工来自逾10个国家，其中女性员工超过53%，女性管理者约45%。2022年，公司DEI工作组启动了全球女性科技理工从业者（WiSTEM）项目，进一步赋能女性职业发展，充分展现榜样“她力量”。目前，公司从事科学、技术、工程和数学（Science, Technology, Engineering, Mathematics, STEM）职位女性占比高达 53%，远高于业界平均水平。
推荐 · 阅读
关于药明生物
- 滑动查看更多介绍 -
WuXi Biologics Receives 2022 "Prime Employers for Women" Silver Award
SHANGHAI,
Nov. 23, 2022
WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), received the 2022 "Prime Employers for Women" silver award at a recent ceremony held by sHero, a non-profit organization dedicated to the development and growth of women. The company was cited for its excellent performance in creating greater Diversity, Equity and Inclusion (DE&I) in the workplace.
WuXi Biologics was also profiled in the 2022 DE&I China Best Practices Guide ("the Guide") for its efforts in promoting DE&I across the company through enriching initiatives and activities. The Guide – jointly published by sHero and Michael Page, a leading professional recruitment agency – features best-practice cases of 30 well-known global companies from various industries such as Ford and SONY Group to help more organizations rise to a greater level of diversity, equity and inclusion in their own work environments.
Dr. Chris Chen, CEO of WuXi Biologics, said, "DE&I, as a vital component of ESG (Environment, Social, Governance), is of great importance to drive forward the continuous innovation and sustainable development of WuXi Biologics. We are very honored to receive the silver award of 'Prime Employers for Women' in 2022 and selected for inclusion in the Guide, which we view as a testimony to the success of our DE&I efforts and ESG strategy. We have integrated DE&I into our PROUD culture to encourage employees to constantly pursue career growth and success. With DE&I and ESG initiatives as a cornerstone of our global business development, and rooted in our mission and vision, we will continue to enable our partners to benefit patients worldwide."
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy. The company is committed to creating a safe, harmonious, and inclusive working environment and an equitable workplace.
There are 10,000+ employees from over 10 countries working at WuXi Biologics. Women hold 53% of all full-time positions, and 53% of those are in STEM (Science, Technology, Engineering, Mathematics) positions, which is much higher than the industry average. In addition, the company has exceeded its target of having over 45% female managers. In 2022, a global WiSTEM (Women in STEM) program was launched across all WuXi Biologics sites to encourage female employees to pursue both professional development and personal growth.
About WuXi Biologics
- Scroll down for more introduction -
媒体关系
PR@wuxibiologics.com
业务垂询
info@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
